Home / Transcripts / Pfizer Inc. (PFE) · February 3, 2026

Pfizer Inc. (PFE) Earnings Call Transcript & Summary

February 3, 2026

New York Stock Exchange US Health Care Pharmaceuticals earnings 74 min

What were the key takeaways from Pfizer Inc.'s February 3, 2026 earnings call?

In the fourth quarter of 2025, Pfizer Inc. (PFE:US) reported revenues of $17.6 billion, down 3% year-over-year, primarily due to a significant decline in COVID-19 product sales. However, excluding these products, operational revenue grew by 9%. The company achieved adjusted diluted EPS of $0.66, exceeding expectations, driven by strong gross margins and effective cost management. For fiscal year 2026, Pfizer maintained its revenue guidance of $59.5 billion to $62.5 billion and adjusted diluted EPS guidance of $2.80 to $3.00, reflecting anticipated growth from non-COVID products and ongoing investments in R&D.

What topics did Pfizer Inc. cover?

What were Pfizer Inc.'s February 3, 2026 results?

Pfizer's fourth quarter results reflect a solid operational performance despite challenges in the COVID-19 segment. The reaffirmation of guidance and focus on pipeline advancements, particularly in obesity and oncology, provide a positive outlook for the company's growth trajectory. Investors should monitor the execution of its strategic initiatives and the impact of upcoming product launches and patent expirations on revenue streams.

Earnings Call Speaker Segments

Francesca DeMartino executive
#1

Hello everyone, and thanks for joining Pfizer's earnings call this morning. Francesca DeMartino here, I serve as Chief Investor Relations Officer. We at Pfizer appreciate you being with us today; you can access this call through audio webcast at pfizer.com. This morning, we put out our results covering the fourth quarter along with the full year 2025 through a press release, and that's up on our website at pfizer.com. With me today are Dr. Albert Bourla, our Chairman and CEO; Dr. Chris Boshoff, our Scientific Officer — Chief Scientific Officer; and Dave Denton, our CFO. Albert, Chris and Dave will offer some prepared remarks, after which we'll take questions from the call. Our leadership team members will be on hand for the Q&A session. Before we begin, please remember that forward-looking statements will be made and certain non-GAAP financial measures discussed. Please take the time to review the disclaimers in our slide presentation, the press release issued this morning and the disclosures in our SEC filings, all of which can be found on the IR website at pfizer.com. Forward-looking statements made on the call carry substantial risks and uncertainties, reflect our views only as of the call's original date and we hold no obligation to update or revise any of the statements. With that, I'll hand the call over to Albert.

Albert Bourla executive
#2

Francesca, thank you. Well, 2025 turned out to be an excellent year for Pfizer. Strong execution pleased me greatly, as we met and honestly surpassed what we had promised financially. Revenue and adjusted diluted EPS both came in above what had been expected, and we also gave back $9.8 billion to shareholders through our quarterly dividend. Setting aside COVID-19 products, operational revenue climbed for the full year 2025, we posted solid double-digit growth among recently launched and acquired products, and adjusted gross margins went up. Thanks to strategic moves in 2025, we cleared up a lot of uncertainty — gaining better visibility on pricing and tariffs, and showing how resilient the underlying business is, delivering EPS even through the weakest COVID-19 season we have ever seen. Four key approvals were secured, along with eight critical readouts, and 11 pivotal studies got underway. Meanwhile, our deals with Metsera, YaoPharma and 3SBio made our already strong pipeline even stronger. All in all, 2025 showed just how well Pfizer can execute. We bolstered our foundation, putting us in position for growth as the decade nears its end, ongoing impact for patients, and long-term shareholder value. Once again we have set our strategic priorities for the coming year, which we laid out at JPMorgan. 2026 matters a great deal — it falls within a pivotal stretch of investment as we push for industry-leading growth once several key products lose their patent or regulatory exclusivity over the next few years. Among our most significant strategic acquisitions of recent years are Seagen, Metsera and Biohaven; their potential to transform Pfizer is real, and our focus is on getting the most value from in-line product portfolios while speeding up pipeline development. Progress continued last year as we brought legacy Seagen products into our commercial portfolio. I am likewise pleased by notable strides in our development programs, among them a recent FDA approval for Padcev combined with pembro for muscle-invasive bladder cancer patients who cannot receive cisplatin-containing chemotherapy; we see encouraging opportunity to build on that with an expected regulatory decision for cisplatin-eligible MIBC patients. Should that succeed, we will greatly enlarge the U.S. addressable population, adding up to roughly 22,500 patients across both cis-eligible and cis-ineligible muscle-invasive bladder cancer, compared with about 19,000 patients in metastatic urothelial cancer. Our strategy is clear: we aim for Pfizer leadership in the next generation of chronic weight management therapies, drawing on a highly differentiated Metsera pipeline portfolio, our exclusive global collaboration and licensing agreement with YaoPharma, and other Pfizer programs such as our oral GIPR antagonist candidate. Since our Biohaven acquisition closed a few years back, we have scaled a leading migraine portfolio worldwide. That improved our product mix, driving meaningful impact for patients and for our commercial results. Nurtec holds a strong market leadership position within the oral CGRP class in 2025. During Q4, we took 83% of new CGRP writer volume and stayed the leader in new patient starts. I expect 2026 will also be a very rich year for key catalysts, and we intend to deliver on our critical R&D milestones. Looking ahead to this year, we expect movement on roughly 20 pivotal studies that were either recently begun or are in the planning stages. Ten of those sit within the Metsera portfolio, and four involve our anti-PD-1 VEGF bispecific. Out of eight key readouts we're expecting, one covers SV — our novel vedotin ADC aimed at integrin beta 6, which has the potential to be first-in-class. That readout concerns second-line-plus non-squamous metastatic non-small cell lung cancer, a setting affecting roughly 50,000 patients in the U.S. and over 200,000 worldwide. Beyond that, we look forward to key Phase III data for Elrexfio in double-class exposed relapsed, refractory multiple myeloma, as well as for our Lyme disease vaccine candidate. Our approach in obesity and adjacent condition rests on pursuing breakthrough medicines in what may be a $150 billion market. Earlier today, we shared encouraging results from the VESPER-3 study — formerly called MET-097i — the ultra-long acting investigational next-generation injectable GLP-1 receptor agonist. Shortly, Chris Boshoff, our Chief Scientific Officer, will take you through further specifics and our plans to move the obesity portfolio forward this year. Oncology represents another area of strength, and I'm eager about the chances for meaningful advances in 2026 that would extend our established footprint in breast, genitourinary, thoracic and gastrointestinal cancer and, naturally, blood cancer; alongside promising programs like SV, our Oncology team is advancing rapidly with a substantial program for '4404, the bispecific antibody we licensed last year from 3SBio. Seven trials for '4404 are planned near-term or have recently started, among them two large global Phase III studies, underpinning our push to establish this investigational medicine as a possible backbone therapy spanning multiple tumor types. We're likewise pleased that the FDA has awarded HYMPAVZI Breakthrough Therapy Designation for investigation in younger pediatric patients aged 6 to 11 with hemophilia B, with or without inhibitors; that's a significant innovative medicine today, and we're exploring the full potential of HYMPAVZI to help more people living with hemophilia. Investing to maximize post-2028 growth is our third strategic priority. We're committed to fully backing a robust and accelerated approach to R&D, the successful commercial launch of new products and bolt-on business development while sustaining our robust dividend; last, we're scaling artificial intelligence across R&D, manufacturing, commercial and patient engagement to boost productivity and speed up innovation. We've been laying the groundwork with AI-ready data, agentic workflows and compute capacity. To satisfy rising AI demand over the next 2 years, we're expanding to more than 1,200 GPUs, mostly driven by R&D application of AI. Within R&D, we're embedding AI throughout discovery, development, regulatory and medical to raise productivity and accelerate the pipeline and time lines. AI is optimizing supply planning and manufacturing, contributing to our Manufacturing Optimization Program goals. On the commercial side, AI is helping speed new product launches, delivering insights for dynamic targeting and supporting personalized messaging and real-time marketing content. Alright, having laid out those four priorities, which together give the complete view of our 2026 plans, I'll now hand things to Chris so he can walk through today's news — the Metsera long-acting announcement regarding VESPER-3. Chris?

Chris Boshoff executive
#3

Thank you, Albert. It's a pleasure to be here today to talk through the VESPER-3 study results and add some further detail to this morning's press release. For our obesity portfolio, these data represent a significant step forward, since they substantially boost our confidence in the Phase III trial of monthly dosing that we anticipate launching later this year. First, let me go over the way PF'3944's structure produces its long half-life. Older GLP-1 receptor agonists that depend on albumin binding for half-life extension must dissociate from the albumin protein before they can engage the receptor optimally. Since the fatty-acid modification on '3944 is located at the far end of the peptide rather than in its interior, the molecule can still engage the GLP-1 receptor while remaining bound to albumin. That translates into reduced clearance without any sacrifice in receptor binding, which gives it a longer half-life than compounds that must first separate from albumin before they can bind. A key thing that sets '3944 apart is precisely this prolonged half-life, and it's what allows for once-a-month administration. On top of that, '3944 is made up of 41 amino acids, so it qualifies as a biologic and can therefore go through the BLA review pathway. On the right side of this slide, you can see previously reported Phase IIb VESPER-1 data, in which '3944 was given weekly and without titration; those results demonstrate dose-dependent, placebo-adjusted weight loss reaching 14.1% by week 28, which shows the molecule's potential for efficacy that competes with the standard of care and may be best-in-class among mono-agonists. Our ongoing weekly Phase III trial of '3944, VESPER-4, is also evaluating a higher dose, 2.4 milligrams per week. For VESPER-3, there were a couple of main objectives we set out to hit. The first was demonstrating that patients can keep losing weight after transitioning from shots given every week to ones administered subcutaneously once a month — this maintains the effectiveness of '3944 while reducing how often doses are needed by a factor of four. The second objective involved proving that '3944 is able to move to a monthly dose that's equivalent to four times the original, all while maintaining a safety profile that's both well tolerated and favorable. I'm going to walk you through the data now, and what they reveal is that both of these objectives were achieved. As for the VESPER-3 Phase IIb trial, its purpose was evaluating '3944 using monthly maintenance dosing following a titration phase that could run as long as 12 weeks. This trial includes four separate dose schedules, all measured against a placebo, with a tolerability review planned in advance for week 12 and the main reporting point set at week 28. The two groups whose results we're sharing now are Arm 1 and Arm 3 — the low and medium dose schedules that we plan to advance into Phase III. Starting with the first goal, I'm glad to say we observed strong weight reduction that was statistically significant across all doses tested. At week 28, the weight loss adjusted for placebo came to 10% for the low Phase III dose and 12.3% for the medium one; those figures appear in the blue bars and serve as the trial's efficacy estimate. The teal bars show projections from our model regarding how effective '3944 might be when given as a monthly maintenance dose. These projections are for a trial similar to VESPER-3, involving adults with obesity or excess weight who don't have type 2 diabetes. We generated these estimates through a model-based meta-analysis approach, which uses a mathematical framework to describe both the way weight loss changes over time and how response relates to dose. Building this model drew on observed results from VESPER-3, information from other '3944 clinical trials, and published data on competing weight loss treatments. Looking at the low and medium dose regimens, there's strong agreement between what we saw in our VESPER-3 clinical data — that's the blue — and what our model predicted, which is the teal. If we take that same model and use it to estimate how well the planned Phase III high-dose regimen might work — 9.6 milligrams given monthly — we project placebo-adjusted weight loss of close to 16% by week 28. It's worth noting that the high dose is already being evaluated in the VESPER-4 Phase III study, given as 2.4 milligrams weekly. So when you put our clinical data together with our model predictions, they show that '3944 can deliver robust weight loss once patients move to monthly dosing, and they suggest we might be able to get even greater efficacy at a higher dose. On top of that, the VESPER-3 findings show there's no point at week 28 where weight loss stalls out, which means patients should keep losing weight as the trial continues all the way to week 64. With that kind of data in hand, our confidence is high that '3944 could provide efficacy on par with the standard of care and maybe even best-in-class status among mono-agonists, thanks to a monthly dosing approach that sets it apart. Turning now to VESPER-3's second goal — showing that '3944 is well tolerated and has a favorable safety profile when patients move to a monthly dose that's 4-fold equivalent. Just like with the first objective, I'm happy to say '3944 came through again. Within VESPER-3, '3944 has demonstrated a well-tolerated and favorable safety profile in line with what's been observed for weekly GLP-1 receptor agonists. The gastrointestinal side effects that showed up during treatment were mostly on the mild to moderate end. No dose group had more than a single case of severe nausea or vomiting, and severe diarrhea didn't occur at all. When we look at how many people stopped treatment during both the weekly and monthly phases of VESPER-3, the picture is quite favorable. For every dosing schedule we intend to carry into Phase III, five patients in the weekly phase and five in the monthly phase halted treatment because of adverse events. In the placebo arm, there were zero such discontinuations. These findings give us real encouragement — they represent a meaningful proof of concept that our monthly dose at 4-fold equivalence can be delivered while keeping tolerability competitive, especially since the protocol placed no restriction on down titration. All the tolerability information we've gathered backs up what we intend to do next: test a larger monthly dose, 9.6 milligrams, during Phase III. That monthly amount matches what 2.4 milligrams given each week adds up to, and that weekly dose is what the ongoing VESPER-4 trial is currently examining. The positive findings we're sharing today give extra momentum to our broad obesity efforts. Looking at this year, we want to advance over 20 studies in obesity, among them 10 Phase III trials for '3944, spanning chronic weight management, conditions that accompany obesity, and opportunities to give patients more choices and better access. When it comes to a first approval among what could be several, 2028 is the year we're targeting. Now, on the earlier-stage side of things: we have a lot of enthusiasm for the Phase II work with our ultra-long-acting amylin analog. Our belief is that it can produce efficacy at the top of its class, and that it can be paired with '3944 in a once-a-month dosing schedule. Previously, we reported favorable early findings from the single ascending dose combo trial, showing starting doses that were well tolerated and weight loss that was additive. We plan to share updated data on the combination later in the year. Meanwhile, we're continuing to advance what may be a first-in-class oral GIPR antagonist, currently in Phase II, along with further Phase I trials of compounds across a range of modalities and mechanisms — including an ultra-long-acting injectable GIPR agonist, an injectable GLP-1 receptor agonist that could potentially be dosed quarterly, and oral candidates. To wrap up, the results we're reporting today are unambiguous. VESPER-3 came through on both of its primary goals: it backed up the promising potent and tolerable once-a-month profile for '3944. As an ultra-long-acting GLP-1 receptor agonist, our drug serves as the backbone of an obesity portfolio under investigation that sets us apart, producing strong weight reduction with no sign of a plateau at week 28 in VESPER-3, and preserving tolerability that competes well when patients move to a monthly dose equal to 4-fold. We stand ready to run a broad Phase III program for '3944, aiming at a possible approval beginning in 2028; and we're also going after distinctive combination strategies involving earlier-stage agents that might offer more optionality in tackling the varied unmet needs of patients; with that, I'll pass it back to Albert.

Albert Bourla executive
#4

Appreciate that, Chris. What I'd like to note is that the numbers we're sharing today amount to strong proof of our distinctive, patented ultra-long-acting peptide platform. We've demonstrated, for the very first time, that GLP-1 receptor agonist peptides are able to be dosed on a monthly basis and still keep the potential for efficacy and safety that can compete. This milestone matters a great deal for the platform, and we're happy with it, since it strengthens both how our technology stands apart and the sizable opportunity for creating long-term value that it represents. So, with that said, I'll hand things over to Dave, who will walk through the outstanding results for the quarter. Dave?

Dave Denton executive
#5

Okay, thanks Chris and Albert, and good morning to all of you. I want to start off right now by pointing out that the robust financial results we posted for Q4 and for the entire year are a direct mirror of how consistently we've kept executing against our main strategic objectives; we cleared up some major and meaningful uncertainties within the business and put strategic investments to work that are intended to fuel revenue expansion later in this decade and past it. As we look forward, Pfizer is entering a promising period, one in which products recently launched or acquired, together with a robust pipeline, are expected to accelerate growth as this decade draws to a close. Okay, so first thing this morning, I want to take you through how we did across the entire year and in Q4 — that's full year and fourth quarter 2025 results — and then I'll get into the programs we have for improving costs, plus how we're thinking about where capital goes. After that, I'll close with a few quick comments on our '26 guidance, and we're reaffirming that guidance today. For full year 2025, revenue came in at $62.6 billion, versus $63.6 billion the prior year, a 2% decline on an operational basis. The key point is that if you take out what our COVID-19 products contributed, our operational revenue growth was 6%. And adjusted gross margins for full year 2025 came in at 76%, which is wider, and right in line with our expectations. Going forward, we'll continue driving cost reductions across our entire manufacturing footprint. Turning to the bottom line, our full year 2025 diluted EPS came in at $1.36, down from $1.41 the prior year, while adjusted diluted earnings per share reached $3.22, up from $3.11 LY, surpassing what had been anticipated. During the full year of '25, the products Pfizer has newly launched or acquired brought in $10.2 billion in revenues, growing about 14% operationally versus a year ago; we plan to keep funding these two product groups to drive their future results, which should allow the company to partially offset our LOEs over the next several years. Moving on to Q4 of 2025, our revenue came in at $17.6 billion. That represents a 3% drop on an operational basis versus the prior-year quarter, driven largely by a roughly 40% operational year-over-year slide in our COVID offerings. The main reasons for that decline were Comirnaty receiving a restrictive vaccine recommendation in the U.S., along with Paxlovid, where demand fell because infection rates were lower. Even so, our non-COVID products turned in a strong performance, growing 9% operationally against the year-ago period. What these numbers demonstrate is how effectively our updated commercial approach is paying off. We got solid contributions across the portfolio, with Abrysvo, Eliquis, Prevnar and the Vyndaqel family doing most of the heavy lifting. For Q4, adjusted gross margin landed at about 71%. The main drivers were the quarter's product mix — Comirnaty sales were lower than in Q4 of '24 — along with our ongoing disciplined approach to costs. Making further gains in our manufacturing footprint remains a leading priority going forward. Keep in mind that, excluding Comirnaty, our adjusted gross margins have typically held in the mid- to upper 70s across the last 2 years; Comirnaty carries a 50 to 50 profit split with BioNTech, our partner. Through 2025, Phase 1 of our Manufacturing Optimization Program delivered savings of roughly $600 million, and we anticipate additional savings in '26 and '27. Looking at Q4 of 2025, our adjusted operating expenses totaled $7.4 billion, essentially flat versus the prior year. Breaking that down by line item, though, adjusted SI&A fell 5% on an operational basis, driven largely by targeted investments and continuing productivity gains. Those factors produced declines in marketing and promotional outlays across a range of products, along with lower costs in corporate enabling functions. On adjusted R&D, we saw a 4% operational increase, primarily reflecting greater investment in oncology and obesity candidates. Partially balancing that out was a net reduction tied to pipeline prioritization and optimization efforts, which include scaling up our digital capabilities. Turning to the bottom line: for Q4, diluted GAAP performance on a reported basis showed a loss of $0.29 per share. When looking at adjusted diluted earnings per share, we posted $0.66, exceeding what we had anticipated, driven by how well we managed gross margin and costs. To help advance our objective of boosting R&D productivity and concentrating on medicines with high impact, our GAAP results for the fourth quarter show choices we made strategically regarding development plans, along with a revised long-range revenue projection for certain products and pipeline assets. Consequently, we booked roughly $4.4 billion in noncash intangible asset impairments tied to a number of medicines still in development, plus products already on the market. One thing worth flagging: we chose to put less emphasis on a particular asset indication, namely disitamab vedotin in bladder cancer. The main driver there is that Padcev has recently posted strong study readouts along with expanded indications and correspondingly higher long-term revenue projections. Padcev remains something we'll keep funding, which lowers how much DV in bladder cancer is worth to us. I'd add that impairment calls rest on how individual assets are valued right now, yet taken as a whole, the Seagen portfolio is moving forward faster than we had anticipated. What these choices reflect is our commitment to both future growth and innovation. Looking at our productivity initiatives, we should capture most of the $7.2 billion in total net cost savings we've been expecting by the time 2026 wraps up. From Phase 1 of the Manufacturing Optimization Program, we're anticipating another $700 million during '26, plus $200 million in '27 — bringing cumulative savings to $1.5 billion by the close of '27. Beyond that, our cost realignment program outperformed the targets we'd set through '25, and consistent with what we've said before, the R&D savings we achieved in '25 through that cost realignment program are slated to be put back into the business in '26, which is factored into the R&D guidance range we've given for '26. Our cost realignment initiative is still on track to deliver the $5.7 billion in total net savings we've been targeting, with that figure expected to be reached by the close of '26 — the point at which our savings pledge under the program will be fulfilled. Going forward, we'll keep concentrating on uncovering further productivity improvements and efficiency opportunities. Now, I'd like to touch briefly on our approach to capital allocation, which is a strategy designed to enhance shareholder value over the long term. That approach involves sustaining our dividend and increasing it over time; putting money back into the business at a suitable rate of financial return, plus, down the road, the possibility of share repurchases that add value; and during '25, we gave back $9.8 billion to shareholders through the quarterly dividend; we put $10.4 billion into internal R&D and spent roughly $8.8 billion on business development deals, chiefly reflecting the Metsera acquisition and the 3SBio licensing deal. Also, keep in mind that our leverage should finish 2025 close to our 2.7x target once the Metsera transaction closes. Yet, because of LOE headwinds over the coming few years, we anticipate leverage staying around this present level or a bit above it throughout the LOE period. In addition, the planned divestiture of our ViiV stake will further strengthen our balance sheet. Counting the ViiV proceeds, we hold roughly $7 billion in BD capacity. Let me now turn quickly to the guidance we've provided for full year '26, and as I said before, there's no change there. For the whole company across that year, we're expecting revenue in the range of $59.5 billion to $62.5 billion, and adjusted diluted earnings per share for full year '26 should land somewhere between $2.80 and $3. That reflects what we expect to be strong performance coming from across our product portfolio, along with an adjusted gross margin in the mid-70s and a continued focus on keeping tight control of costs, even as we keep putting investment dollars into the business so we can drive growth as this decade comes to a close. On our COVID products, we're looking at another decline in '26, with revenue of roughly $5 billion. We continue to expect consistent top-line input from the part of our business that isn't tied to COVID. Built into that view is an assumption that about $1.5 billion of revenue will be squeezed out as products face generic competition starting in '26. If you look at the midpoint, sales outside of both COVID and LOE items ought to grow roughly 4% on an operational basis versus last year. One last thing worth mentioning: we'll continue monitoring how currencies move as the months go by. And to close, I want to reiterate that across the next several years, our focus centers on putting money into key assets while managing the LOE waves ahead, mostly between 2026 and 2028. Looking ahead to the close of this decade, expansion ought to be driven by three things: momentum in our R&D pipeline, the business development moves we've already completed, and ongoing gains from products we've either recently brought to market or brought in through acquisition. Our objective is to put capital to work wisely, weighing expense reductions against backing high-value offerings, all designed to lock in durable, long-term growth for our shareholders. On that note, I'll turn things over to Albert and open up the Q&A.

Albert Bourla executive
#6

Thanks, David — and great quarter, congrats. Operator, go ahead and put the queue together.

Chris Schott analyst
#7

I've got what might be a two-part question about the VESPER-3 data. First off, I suppose, could you expand a bit more on the tolerability that showed up here? And maybe more specifically, is there anything further you can share regarding rates of vomiting, or any distinctions you noticed between the mild and moderate dose groups? Then, perhaps on a broader level, if we look at the 2 doses advancing from VESPER-3, it appears you've got a drug with clearly solid weight loss and monthly dosing. Yet at the same time, that weight loss could be somewhat under what was seen with the weekly option or Zepbound. I just wanted your perspective on what kind of role that sort of profile will play in the market.

Albert Bourla executive
#8

Wonderful. And naturally, I'll begin with Chris, who I expect will be the person getting most of the questions today, and I'm happy about that. So — and then perhaps we'll also have the commercial folks say a few words on it. So Chris, why don't you kick things off?

Chris Boshoff executive
#9

Yeah, thank you for asking that. As you know, the complete tolerability dataset is going to be presented by us during our oral session at ADA this coming June. The way adverse events were distributed between the weekly and the monthly arms has left us quite encouraged. One might have anticipated that upon switching patients to a dose 4 times as high, there would be more instances of abrupt discontinuation along with nausea and vomiting — yet that is not what we saw; the distribution looked good for both the monthly and the weekly groups. Keep in mind that in this particular trial, no step-down titration was permitted, something you don't often see in obesity studies; however, down-titration will clearly be allowed when we get to Phase III. On the subject of the various dose levels, low and medium were, as we mentioned, the ones shown today. Testing of the higher dose is underway already in VESPER-4, since earlier prediction models suggested tolerability would be good and that 2.4 milligrams given weekly ought to be evaluated, which is what's happening at present. And for the monthly study, 9.6 will be tested, as was noted.

Albert Bourla executive
#10

Okay, let's turn to Aamir — what's your take on how this works from a commercial standpoint? After that, we'll hear from Alexandre.

Aamir Malik executive
#11

When you examine the clinical data, what it tells us quite clearly, in my view, is that '3944 could potentially provide efficacy from an efficacy standpoint that competes with the standard of care and may even be best-in-class when measured against mono-agonists. So our thinking is that if you take that efficacy and pair it with a reduced medication burden by way of a monthly dose, that's a value proposition likely to resonate with patients, providers, and payers, since persistency and simplicity are important. It also creates the chance for us to move patients from weekly therapy to monthly therapy; so in our view '3944 will be a compelling therapy, period; and on top of that, you add the opportunity that comes from the other assets in our portfolio, along with our commercial capabilities to execute in the U.S. and internationally, and I believe that gives us considerable confidence regarding the commercial potential.

Albert Bourla executive
#12

Yes, and thanks, Aamir. What's caught me off guard about this market up to now, I'd say, is just how strongly it's doing beyond the U.S. So Alexandre, what do you think?

Alexandre de Germay executive
#13

Correct. What's genuinely compelling about this space is the market's magnitude — outside America it's expected to reach $150 billion, and 40% of that actually sits outside the U.S. Two aspects of this category stand out as distinctive and they strengthen the case for these assets. The first one is out-of-pocket spending. Since in the majority of countries, whenever we bring the innovation forward, we must negotiate reimbursement, which frequently results in a lower price. Within this category, we observe strong willingness among patients to pay out of pocket throughout all mature markets, whether that's Europe, Australia or Canada, and the price point we're seeing runs from $250 to $350, which exceeds our expectations. And looking at the most recent launch from our rivals in this category, we notice greater willingness to pay across all those geographies, and in fact also emerging markets, where prevalence is likewise high. The second aspect is time to market, since this will largely be an out-of-pocket category, the period following approval at the EMEA will be immediate and that's where we can actually commercialize those products. So that will also fuel fast penetration into the market.

Albert Bourla executive
#14

Thanks, Alexandre.

Vamil Divan analyst
#15

So maybe picking up from that point, Chris — earlier, during a different question, you touched on reducing the dose in Phase III. Could you go into a bit more detail about how the Phase III trials are being structured and how much room patients have to manage whatever adverse effects come up, and whether that ends up lifting the overall picture relative to what Phase II showed? Then my second thing is really outside of VESPER-3. You said this is going to be at ADA. I'd like to know what additional data might come out of your own programs or out of the Metsera portfolio at ADA? And in particular, for your in-house GIPR, should we expect Phase II results to be shared there?

Chris Boshoff executive
#16

Many thanks for that. Once more, a reminder about the VESPER-3 results we shared today: there are just 2 step-up doses. Normally you'd see 4 or 5 step-up doses to reach the target dose — in this trial, only 2 step-up doses existed. Therefore, the VESPER-6 Phase III protocol is going to evaluate varying titration approaches and, as we noted, the extra 9.6 milligram dose, which right now is under study in VESPER-4 as 2.4 milligrams given weekly. On the next — the remaining portfolio, clearly we're enthusiastic about the platform overall. It's a highly differentiated platform. As you're aware, we've already shown results for the ultra-long-acting amylin '3945, also known as MET-233, in which the additive weight reduction seen from pairing '3944 with '3945 came to 5% at day 8, and prior single-agent ultra-long amylin findings indicated 8.4% placebo-adjusted weight loss at day 36. So later in the year, ADA included, we ought to release fresher data on amylin plus possible early results for the amylin combined with '3944. Also, as you're aware, within our portfolio we're enthusiastic about the remaining Phase II efforts, among them a potential first-in-class oral GIPR antagonist that came from internal discovery and conceptualization, now in the randomized Phase II stage, plus the wider Phase I peptide effort, among them an ultra-long GLP-1 that could be given every 3 months, quarterly, now sitting in Phase I, along with our other oral candidates, among them the oral GLP-1 we recently brought in from YaoPharma.

Albert Bourla executive
#17

Thanks, Chris.

Steve Scala analyst
#18

When it comes to the VESPER-3 data, did the people on placebo put on pounds or shed them? Then my second one isn't about obesity — it's that Pfizer has repeatedly insisted there's nothing past December '28 for Vyndaqel. Is it right to fully dismiss every possible approach, including reaching a settlement with makers of generics, regarding the patents Pfizer holds?

Albert Bourla executive
#19

Thanks, Steve. I'll handle the Vyndaqel part, since I've gotten that question many times. At this point, our assumption is that the patent ends at the close of 2028. Beyond that, there's nothing else I can say. These matters are extremely delicate. So now I'll turn to Chris regarding the placebo group and how much weight came off there.

Chris Boshoff executive
#20

Once more, the complete dataset is going to be shared by us at ADA, though with VESPER-3 specifically, the placebo group turned out quite steady, without much movement either direction, yet the information will be available for you at ADA.

Albert Bourla executive
#21

Fine. Many thanks.

Geoff Meacham analyst
#22

Well done on the results announced today. Once more, several questions regarding the fresh data out today. So in terms of the PK/PD, do you believe you're settled on once-monthly as the maximum interval between doses that maintains effectiveness? Or could it perhaps be possible to go out to dosing once every 2 months? And regarding what you have planned for Phase III, do you feel these will probably be the usual kind of metabolic trials that we would anticipate? Or might you go after some inflammation or neuropsych indications, perhaps? Or would you go after studies with an active GLP-1 comparator? I'm just attempting to consider how you might differentiate yourselves within a wide-ranging Phase III program.

Albert Bourla executive
#23

Yes. Thanks, Geoff. So Chris, once a month or longer. And then further trials.

Chris Boshoff executive
#24

Thank you for asking that. As we've shown, '3944 is the first peptide able to be given once a month, and it's possible we could stretch that further, though with '3944 our goal is monthly maintenance treatment. Like I said, we have a second molecule — a peptide in Phase I right now — featuring a pro-drug, a pro-peptide, that might allow dosing every three months. It's in Phase I at the moment, and within the coming couple of months we expect further PK/PD results from it, which could open the door to a 3 monthly schedule. On your second point, the first Phase III trials, VESPER-4, VESPER-5 and VESPER-6: VESPER-4 covers patients who don't have type 2 diabetes and is running now with weekly testing, including the 2.4 milligram weekly high dose; VESPER-5 involves patients who do have type 2 diabetes, while VESPER-6 is the trial that will feature monthly dosing. Past those, we intend to launch seven studies. We haven't disclosed or shown what those studies will be. Still, you're entirely right that in addition to cardiovascular and metabolic, we're exploring other ways to stand apart, and to stand apart through our combinations too, such as with amylin or with the GIPR now in Phase I.

Albert Bourla executive
#25

Thanks.

Terence Flynn analyst
#26

I might have a second one as well, this time about the VESPER-3 data. I realize you'd prefer to keep much of that data under wraps until ADA, but I was just curious whether you could share any top-line information regarding the baseline characteristics — for instance, BMI or the mix of genders? I understand those can differ from one study to another at times. Then, regarding tolerability, one more question: when dosing intervals are longer, what about how long GI side effects last — is there any qualitative comment you could give, such as whether that runs beyond 1 or 2 days?

Albert Bourla executive
#27

Chris, that one's for you once more.

Chris Boshoff executive
#28

All right. First, regarding the patient characteristics. This research took place solely within the United States. And as I believe you're aware, there are variations, particularly concerning adverse events and tolerability-related dropouts when looking at populations of patients from the U.S. alone; that's the first point. The remaining specifics on demographics are going to be shared at ADA, though they align with what one would anticipate from a Phase II trial of modest size based in the U.S. Now, moving to the following question...

Albert Bourla executive
#29

Which one did we get after that? The tolerability one?

Chris Boshoff executive
#30

Regarding tolerability. Like we've mentioned previously, the overall tolerability has us feeling good. It mirrors what you'd anticipate from the GLP-1 class, though in our case, we're able to go to monthly dosing, with adverse events spread out over both weekly and monthly schedules. That doesn't raise any concern for us that a switch to monthly would all at once produce a bunch of discontinuations or serious AEs. As I noted before too, there's no — only a single case of severe nausea, a single case of severe vomiting throughout the entire program, and no severe diarrhea. So on the whole, the safety profile has us quite encouraged. And once more, at ADA, we'll present the full AE profile.

Albert Bourla executive
#31

Thanks, Chris.

Akash Tewari analyst
#32

Up to now, results for second-line plus NSCLC have looked fairly disappointing when set against docetaxel. Does your team believe it can produce a better profile through the Phase III you have coming up with B6A? Otherwise, will you have to enrich for patients whose B6A expression is high? Could you help set expectations for that readout?

Albert Bourla executive
#33

Chris?

Chris Boshoff executive
#34

So you're referring to sigvotatug vedotin, yes?

Akash Tewari analyst
#35

Yeah.

Chris Boshoff executive
#36

That's right. Okay, so I want to note this is a second-line trial testing against docetaxel — that's the Phase III one — and remember there's another Phase III running too, a first-line trial looking at sigvotatug vedotin combined with pembrolizumab versus pembrolizumab alone in the TPS high, PD-L1 high group. In terms of single-agent activity, the response rate came in above 30%, with median overall survival in that Phase II trial reaching close to 16.3 months. So on the whole, the data has us encouraged. When it comes to the combo trial pairing SV with pembrolizumab, the overall response rate was 57%, and the disease control rate exceeded 90%. So both studies give us confidence. I'm with you that in the second-line setting versus docetaxel, no ADC has truly demonstrated an advantage over docetaxel, yet everything observed to date leaves us feeling good about this trial. It'll be the first one to report. The pembrolizumab-versus-pembrolizumab study reads out second; it's event-driven. Events have been slower than anticipated, which might indicate either arm is doing better, but we ought to bring you an update on those results over the next few months, in the first half of this year.

Albert Bourla executive
#37

Thanks, Chris.

Asad Haider analyst
#38

Good; and I appreciate all the specifics regarding the clinical catalysts. Perhaps only one thing on portfolio realignment, Albert, concerning this recent divestment of your stake in the HIV joint venture with Glaxo, just in general, where do we stand, when it comes to portfolio pruning or realignment, given that you've also recently announced a new reorganization incorporating your global hospital and biosimilars business?

Albert Bourla executive
#39

Chris could weigh in on that too, I think, but allow me, since the question was directed at me. My sense is that the bulk of pruning in our pipeline has now been completed. So what we're continuing with at present, on a broad scale, consists of things we view as worth investing in, and we keep investing. There are extremely few exceptions of items that already existed and where we faced some issues requiring discontinuation or divestment. So from that standpoint, I believe we're performing very well. Chris, anything to add there?

Chris Boshoff executive
#40

Right, so our attention is squarely on those 4 therapeutic areas. Over the course of 2025, we did a lot of prioritization and sharpened our focus for the program, and as you're aware, we found as much as $500 million in R&D savings, and that money is being put back into Phase III programs now. Then this year, like Albert mentioned, we're looking to kick off around 20 Phase III programs, which really moves the portfolio forward.

Albert Bourla executive
#41

Perhaps Dave can also provide some additional detail here. Yet what I wanted to point out is that whenever you mention generating synergies or generating cost reductions in R&D that get reinvested, we are not referring to moving ahead by ending a program — in fact, it involves a greater number of programs; this will come about through AI deployment, which already took place in 2025 with outstanding results that deliver substantial productivity gains. That is exactly where we are lowering R&D expense. And we put all of it back into more programs that, as you can see, include launching 20 pivotal studies in '26. Dave?

Dave Denton executive
#42

Yes, I’ll simply build on what was said there. When we examine the portfolio of products we already sell, we’re constantly checking for ways to get the most value out of them. ViiV serves as a solid illustration of an asset that isn’t strategic for us, and by monetizing it this way, we’re able to put that capital back to work where it can earn better returns down the road. Like you mentioned, we did put together a collection of sterile injectable and biosimilar products, and our attention is on boosting productivity throughout that group of offerings. We’ll keep doing that as we consider where our product lineup is headed.

Albert Bourla executive
#43

Thanks a lot, Dave.

Courtney Breen analyst
#44

Maybe just picking up where the last discussion left off. When you mention those more than 20 pivotal trials kicking off during this year, we're looking at roughly a midpoint of $11 billion as the R&D guidance for '26. So how should we frame '27 once those studies begin to annualize? And then, tying that together with what you brought up a moment ago, Albert, regarding the investment in AI — that 1,200-GPU rollout you're doing — about when and where will we start to notice the effect of that approach? And is that going to change anything in how R&D runs the pivotal trials? Or ought we to be thinking more about innovation on the research side over the longer term?

Albert Bourla executive
#45

Courtney, thank you. That's a really good question. As you can appreciate, no guidance is provided by us for 2027; however, I will ask Dave to offer some color.

Dave Denton executive
#46

Yeah. I suppose, if you look at it in context and just consider R&D, as we move from '25 into '26, given the business development deals we've completed, we've in fact added to the workload and the burden that has to be handled inside our R&D organization. Meanwhile, we're putting roughly $11 billion into R&D. So we're able to be more productive with the infrastructure throughout R&D and absorb more substrate so we can concentrate on making medicines for the close of the decade and past that; so I believe what we're attempting to do is keep refreshing and enhancing productivity throughout our R&D platform in order to put those dollars back into R&D and keep pushing forward the programs we have going and the programs we're building. As you're aware, 2026 is a major starting year for us from a science standpoint; we will keep concentrating on those investments moving ahead.

Albert Bourla executive
#47

Thanks, Dave.

Umer Raffat analyst
#48

If I could, a couple of quick questions. To start with, regarding the GLP monotherapy: can you remind us whether the 9.6 milligram monthly dose came about as a response to today's data? Or had that already been under consideration? Then second, when it comes to the tolerability data now emerging for your GLP plus amylin combo, what's your level of confidence there? Also, do you believe it's possible to put the GLP plus amylin into one pill?

Chris Boshoff executive
#49

All right. Thanks, Umer. Regarding your first question, keep in mind that 2.4 milligrams is already under study as a weekly regimen, making it a high dose in VESPER-4, and that choice was taken on the basis of the modeling-based meta-analysis. And as we demonstrated today, our modeling does a very good job predicting, matching what we in fact saw with what the modeling forecast for 3.2 and 4.8. That gives us confidence in the modeling for 9.6 as well as for the 2.4 milligrams.

Albert Bourla executive
#50

Chris, basically what you say is that the 9.6, it is the 2.4.

Chris Boshoff executive
#51

Correct.

Albert Bourla executive
#52

4x weekly, it is 9.6 monthly.

Chris Boshoff executive
#53

Correct, yes. Any other — what was the second part?

Albert Bourla executive
#54

Combination...

Chris Boshoff executive
#55

Just a quick reminder — that combination is taken monthly, and it's amylin together with GLP-1 ultra-long, given subcutaneously once a month. A pill it is not. An oral portfolio does exist on our side, plus there are additional oral medicines we found in-house that haven't been disclosed yet. As things stand, though, our oral medicines are GLP-1 and GIPR — amylin isn't among the oral ones.

Albert Bourla executive
#56

And how do you feel about this data?

Chris Boshoff executive
#57

Also, at ADA, we're going to present results from the amylin plus GLP-1 monthly program, covering the ultra-long-acting monthly dataset. As a reminder, the previous figures we presented for the pairing of '3944 and '3945 came in at 5% on day 8. Those were preliminary findings that were shared, and we'll be refreshing that information sometime later in the year.

Albert Bourla executive
#58

All right, Chris. Thank you very much.

Jason Gerberry analyst
#59

Sorry about the noise in the background. Given what we learned from today's VESPER-3 update, I'm just wondering how you view the added benefit of combining a GLP-1 with an amylin injectable versus using just the monotherapy? And is your aim really to go head-to-head in that ultra-high efficacy tier against things like Lilly's GGG? Or could the added value lie more with GLP-1 nonresponders? I'm asking because it looks like what you've got with the monotherapy approach might let you compete with Zepbound and MariTide? So I'm just wondering how you see the combo and where it fits.

Albert Bourla executive
#60

Let me have Chris walk through a bit of the science underlying this combination, and after that I'll turn to Aamir and Alexandre for their thoughts on how it could be marketed.

Chris Boshoff executive
#61

Right, so we'll have options here, since in Phase III we're working on both the single agent, '3944, and the combo of '3944 with '3945. From everything observed up to now, it points us — as you were saying — toward the combo giving us better efficacy; so our hope is to bring out updated data later in this year, kick off the Phase II trial during this year, and after that, in the following year, launch the Phase III trial for that combination.

Albert Bourla executive
#62

And then Aamir, how do you see this playing as portfolio?

Aamir Malik executive
#63

Right, Jason. So I suppose the short response is this: listen, we believe we're at the earliest stages of a big market where a substantial unmet need remains, correct? Better dosing convenience is required, greater weight reduction is needed for particular BMI patients, GI tolerability has to get better, maintenance approaches, and there's friction along the patient journey; therefore, in our view no single asset will end up serving every one of those patients. Individuals will arrive with varying starting points, objectives, and preferences regarding their dosing and how the drug is administered, along with different comorbidities and differing willingness to pay. And to succeed in a market of that kind, first, you must have an excellent portfolio of products capable of addressing all of those patient needs; and second, you must possess truly differentiated capabilities; and as Chris has explained, not just our data as of today, but a number of the other items in our portfolio, we have that first element established and building. And our commercial capabilities give us a great deal of confidence, whether that's our field forces, which rank at the top in the U.S. and already call on the majority of GLP-1 prescribers, or the digital platforms we're creating such as PfizerForAll, which have reached more than 25 million patients. So taking all of that together, we hold considerable confidence in our capacity to succeed commercially in this market with these assets.

Albert Bourla executive
#64

Thank you; and Alexandre, any additional?

Alexandre de Germay executive
#65

No.

Michael Yee analyst
#66

I have two things to ask — one is for Chris, the other is for Dave. Regarding the oral GLP-1 you two recently brought in through a licensing deal, could you remind us what level of knowledge you had, or which data were already in hand? My understanding is a sizable Phase I is already underway. That ought to provide a bit of reassurance, but walk us through what was already known about that molecule. Then, Dave, you restated $7 billion of capacity. Could you address whether more is possible, especially considering the recent pause on the dividend — or more precisely, the recent halt to dividend growth — since that kind of move rarely happens, and also share how you're viewing your dividend?

Albert Bourla executive
#67

This time, for a change, I'll begin with Dave, and after that we'll turn to Chris.

Dave Denton executive
#68

Right, so obviously our priority right now is keeping the dividend where it is while also increasing it as time goes on. That makes it a really significant and essential piece and pillar of how we allocate capital; and once more, we do have — heading into this year, we were sitting on $6 billion worth of BD capacity. It's in fact risen somewhat since we announced the pending liquidation of the ViiV asset. That's genuinely a solid illustration of the way we examine the collection of assets we hold inside Pfizer and figure out the best way to monetize them as time passes. So having said that, I'll hand things over to Chris.

Chris Boshoff executive
#69

Much appreciated. YaoPharma's oral small molecule, 5002, doesn't sit on a Lupron scaffold; it's in Phase I right now, and it came to us under an exclusive global collaboration and license agreement with YaoPharma. Our plans include running Phase I studies as well as combination studies alongside our GIPR antagonist, which is presently in the randomized experience in Phase II. At the moment, we're moving all of that work over to the U.S. so that Phase I studies can begin there, manufacturing included in the...

Albert Bourla executive
#70

Thanks.

Alexandria Hammond analyst
#71

One of the main data releases you've pointed to for '26 is the VALOR trial of the Lyme disease vaccine. I've got a few questions about that. When might we hear something new, and if the results are good, what would you expect for the rollout? How does vaccine contracting work, and which channels will matter most for you? And then, last thing, how large could this chance actually turn out to be?

Albert Bourla executive
#72

Right, Lyme disease?

Chris Boshoff executive
#73

Thank you. I appreciate it. Let me kick things off, and thanks so much. For Lyme disease, this has the potential to be a first-in-class vaccine — the Phase III VALOR trial. It's a multivalent protein subunit vaccine aimed at all 6 outer surface proteins of Borrelia burgdorferi. We anticipate that the study will read-out in the first half of this year. As a quick reminder, roughly 400,000 people in the U.S. and 132,000 people in Europe are affected by Lyme disease. And as you're aware, there's significant long-term morbidity and long-term sequelae. So a vaccine specifically in certain regions of the world could be very, very important.

Albert Bourla executive
#74

Thanks, Chris — we can’t wait to see what that data shows. It might represent a major answer for a medical need that hasn’t been met.

Mohit Bansal analyst
#75

Moving on to another point regarding the VESPER program. I'd appreciate some clarity on the target profile being considered for the Phase III study. The reason I ask is that when it comes to GLP-1, you tend to observe weight reduction in the mid- to high teens with an optimized GLP-1. And should you attempt to go past that, tolerability problems could likely begin to emerge. What gives you confidence that this longer-acting GLP-1 might deliver greater weight loss than that while offering improved tolerability? Or do you believe that a monthly option is likely the main distinguishing factor in this case?

Albert Bourla executive
#76

Chris?

Chris Boshoff executive
#77

Thanks a lot — it's really both things. We're looking for weight loss that stacks up well against the competition, and the data we presented today, the predictions included, what you should anticipate from 9.6 milligrams at 16% weight loss — that was projected at week 28; it's very competitive, and tolerability is very competitive too. And then, naturally, there's monthly dosing, which is going to stand apart in a big way. One more thing to note: a Phase III trial is in the works that will look at switching. That means patients who are already doing fine on weekly therapy would move over to monthly dosing.

Albert Bourla executive
#78

Thanks, Chris. And of course, this isn't just about our product, going from weekly to monthly, but about any other GLP-1s available on the market as well, and they wish to transition once they've achieved weight loss into maintenance with just one injection instead of four. Naturally, oral options exist too, though that means moving from one weekly to one daily pill. Some patients will make that choice, but I believe our research indicates that most would prefer — assuming they're already comfortable with a needle — to switch mainly to a more convenient needle, which is once a month.

Evan Seigerman analyst
#79

I wanted to ask about what you said regarding AI investment. What kind of metrics are you attaching to it? And on a wider level, I just want to make sure this will produce a solid return on your adjustment rather than simply adding to the hype.

Albert Bourla executive
#80

That's a great question, and I'll begin, but then I'm going to ask — particular marketing wins and R&D wins driven by AI; overall, there are elements in AI, but the technology is ready at this point. And those are being rolled out extremely, extremely quickly. And of course, I can't do all of it, but certainly can do more than what is being used at present. And that relates to how well you succeed at implementing it, embedding it into your organizational footprint, embedding it into your business processes and also building AI literacy among the employees who ultimately use this AI. That clearly touches everything from enabling functions, and perhaps Dave can talk a bit about what we're doing in that area. I mean, when I mention enabling functions from finance, HR, legal, you name it; and naturally, in R&D, where we've already witnessed substantial productivity gains; in marketing, where it is helping us maximize the ROI at this moment. And in manufacturing, where a very large portion of the savings that were achieved came from a successful deployment of an AI use case known as the Golden Pass. Chris, would you like to provide some specific examples?

Chris Boshoff executive
#81

Absolutely, and I appreciate you raising that. As you mentioned, within R&D we are integrating AI into every function — that includes discovery, medical, regulatory, safety, pharmacovigilance, and clinical trial execution — and we are hiring AI engineers and placing them inside each of those areas so they collaborate with the scientists and clinicians. When it comes to gauging success, it's about productivity. Productivity means both speed and cost. By integrating AI, we reduce expenses and, clearly, we also increase speed.

Albert Bourla executive
#82

How does that look on the commercial side?

Aamir Malik executive
#83

Yeah. Evan, metrics really sit at the core of all our AI efforts. Let me share two concrete illustrations with you. First, field force productivity. Through AI, we're not just assisting in training our field forces — we're also helping them get the most out of their time with physicians. That means physicians get more of our time, and less of it goes to screens. The second one concerns marketing, where MROI is what we track. As Dave mentioned, you've watched how disciplined we've been with our SI&A spend, especially while we work to grow revenue across many of our launch and acquired brands, and AI has certainly played a part in lifting our MROIs, thanks to far more precise targeting of where the money goes.

Albert Bourla executive
#84

Thank you. Alexandre, you did fantastic things also in international with AI.

Alexandre de Germay executive
#85

Correct, absolutely. What I'd say is that at each point in our dealings with a customer, there's room for AI-driven enhancement. Take pre-call planning as an illustration — our reps genuinely perform it at a higher standard when AI is involved. We capture and review how the conversation went, which lets us replay those exchanges and thereby lift the standard of the engagement; AI also enables us to target more effectively, giving us superior targeting capabilities. And then consider this: running a business across the globe, where rules differ widely from place to place, means each nation has to rework and re-evaluate all of its promotional materials. AI lets us handle that in an instant across every one of those markets; there's no need to repeat those tasks country by country; the resulting boost to productivity and the speed at which we reach the market is enormous.

Albert Bourla executive
#86

And Dave, perhaps...

Dave Denton executive
#87

Yes. Maybe just a couple of things. Looking at it from the enabling functions angle, I think about AI in terms of us utilizing our vendors, since we have major vendor technology platforms throughout our entire enterprise. And as they put money into their platform, we are capitalizing on that and integrating those into our processes, which is boosting our productivity. And then second, consider our business model — we have routine transactions, yet we have a huge number of products spanning literally hundreds of markets; so AI is letting us take those datasets and basically automate a portion of those transactions, making it extremely efficient that — currently, we allocate resources in order to accomplish that; so at this point the technology is allowing us to be far more productive.

Albert Bourla executive
#88

Right, so to wrap things up, Evan — that's the reason we listed this among the four imperative strategic priorities we intend to pursue, namely scaling up, since we've enjoyed such significant success. A lot of folks keep asking how Pfizer managed to remove such a large amount of cost from its operations while the top line stayed unaffected. Well, AI is the answer. It isn't simply that we trimmed cost — what we actually accomplished was a gain in productivity. And the primary lever — naturally, simplification work was happening too. Yet the primary lever turned out to be deploying AI successfully, whereby essentially we lower the cost while that reduction doesn't show up in the activity. So I'm quite enthusiastic about what AI could bring.

David Risinger analyst
#89

David, your question is for Chris. Chris, can you expand a bit on MET-233i, which I understand now carries the number '3945? In particular, how does the amylin bias compared with calcitonin, what does that mean for efficacy and tolerability, and what data should we look for at ADA?

Chris Boshoff executive
#90

Thanks so much for asking. This is an amylin with ultra-long action, and it was shown before to deliver, as a monotherapy, 8.4% weight loss adjusted for placebo by day 36. It's a dual molecule, so there's no bias toward the one. Placebo-like tolerability was demonstrated earlier with the monotherapy. That gave us confidence to begin combining '3944 and '3945. Earlier data at day 8 showed 5% weight loss, though clearly that's quite early. We'll provide an update on those data later this year. This combination matters a great deal to us, since we think it can achieve best-in-class efficacy with monthly dosing, which would be highly differentiated for this combination.

Albert Bourla executive
#91

Thanks, Chris.

Louise Chen analyst
#92

First off, I'd like to ask — it's now been a couple of years since the Seagen acquisition closed. I'm just wondering, how has that integration played out? And beyond that, in what ways has that deal actually strengthened your position as a leader in oncology? Then a second, quick question about your PD-1-VEGF. That space is getting more crowded. So I'm just curious — where do you see yourself standing out when it comes to your pipeline? I mean, some indications are arriving ahead of yours, but is there anything particular you'd want to highlight?

Albert Bourla executive
#93

Thanks, Louise. And obviously Seagen has been brought together across research, commercial, manufacturing and several other levels. But since Chris was the person leading that integration through the first delicate year, Chris, perhaps you'd like to say something about how bringing Seagen together went and how it's still proceeding.

Chris Boshoff executive
#94

Thanks a lot for that question. To begin with, Seattle is home to a lively scientific and clinical community. In the biotech and biopharma sector there, I think we rank among the largest employers. A great many of our colleagues chose to stay with Pfizer, which speaks to the strength of our culture and to how well the integration has gone. Quite a few programs have been launched and sped up, among them the readouts you saw with 303 and 304 for Padcev. Another Phase III trial for Padcev is in the works, set to kick off later this year. That study matters a lot to us and to patients, since it aims to potentially do away with cystectomy, which, as everyone knows, brings substantial morbidity and mortality. We also pushed several other programs faster into Phase III, among them SV, with 2 Phase III trials now running and one more Phase III trial about to begin. Then there's PD-L1V, another Phase III effort underway in non-small cell lung cancer, plus a variety of differentiated Phase I ADCs, such as ones that use the integrin beta-6 antigen as a marker alongside new payloads, among them TOPO2 and a novel auristatin-based payload. So all in all, bringing Seagen in is going extremely well. As for '4404, it's a differentiated molecule. In the preclinical findings, we observed a 100-fold rise in affinity for PD-1 when VEGF was present, along with binding across all VEGF-A isoforms. So the preclinical results are quite promising. On the whole, we're upbeat about where the field stands right now. As you're aware, we lately saw positive first-line non-small cell lung data out of China. What we've observed when '4404 is combined with chemotherapy looks very encouraging; and as we move the program along faster, as you've seen, we've already begun Phase III trials for colorectal cancer; and before this year is out, we'll also launch first-line Phase III work in non-small cell lung cancer, followed by endometrial cancer and bladder cancer, including combinations with our ADC portfolio.

Albert Bourla executive
#95

Thanks, Chris. This is truly thrilling, so I appreciate all of you being here. Obviously, I take great pride in the results we delivered during 2025 across several dimensions. The final component came to light today through our fourth quarter numbers, and those were outstanding; we exceeded expectations by a wide gap on both revenues and earnings, even as we faced the mildest COVID season ever, which produced the smallest revenues ever recorded, given how gentle that strain turned out to be. At this point we're already into 2026, and that makes it a crucial year, since it represents the opening year of an LOE cycle that has, in fact, already begun during this year. We have spent many years getting ready for this through the acquisitions we completed, along with strategic and licensing agreements, and at the same time we were honing our attention on the internal programs with the greatest impact. Our commercial teams in the U.S. and internationally have fine-tuned their models to reinforce leadership across key product portfolios, and streamlining plus financial discipline remain, of course, continuing priorities. We'll keep making strategic investments aimed at future growth and value creation for our shareholders, which includes sustaining our dividend and growing it over the long term. Our strategic agenda for 2026 is well defined, and I have confidence in the progress we're going to make. I appreciate your interest in Pfizer, and we're eager to keep sharing our progress with all of you throughout the coming year. Thank you.

Operator operator
#96

Thanks. That wraps up the meeting for today. We’re grateful for your time and for joining in. You can go ahead and disconnect now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Pfizer Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Pfizer Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.